Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3558
Gene Symbol: IL2
IL2
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.330 Biomarker BEFREE We therefore evaluated the safety, tolerability, and antitumor activity of hu14.18-IL2 given with GM-CSF and isotretinoin in a schedule similar to standard MRD therapy. 31358541

2019

Entrez Id: 3558
Gene Symbol: IL2
IL2
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.330 Biomarker BEFREE New approaches to treating neuroblastoma MRD that are in early clinical trials include the cytotoxic retinoid fenretinide and the hu14.18-IL2 immunocytokine. 15125707

2004

Entrez Id: 3558
Gene Symbol: IL2
IL2
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.330 Biomarker BEFREE Has IL2 a role in the management of minimal residual disease for acute leukemia? 1434844

1992

Entrez Id: 1437
Gene Symbol: CSF2
CSF2
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.310 Biomarker BEFREE The demonstration of molecular remissions, analysis of cytotoxic T lymphocytes against autologous tumor targets, and addition of granulocyte-monocyte colony-stimulating factor to the vaccine formulation provide principles relevant to the design of future clinical trials of other cancer vaccines administered in a minimal residual disease setting. 10502821

1999

Entrez Id: 2322
Gene Symbol: FLT3
FLT3
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE FLT3 inhibition in the setting of minimal residual disease and a new immune system via allogeneic transplantation offers a promise of improved survival for these patients. 31550496

2020

Entrez Id: 4869
Gene Symbol: NPM1
NPM1
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 GeneticVariation BEFREE For acute myeloid leukemia (AML) with nucleophosmin 1 mutation (NPM1m), multiparameter flow cytometry (FCM) and real-time quantitative polymerase chain reaction (RQ-PCR) are used to monitor minimal residual disease (MRD). 31768677

2020

Entrez Id: 6962
Gene Symbol: TRBV20OR9-2
TRBV20OR9-2
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE Rearrangements of T- and B-cell receptor (TCR and BCR) genes are useful markers for clonality assessment as well as for minimal residual disease (MRD) monitoring during the treatment of haematological malignancies. 31587259

2020

Entrez Id: 596
Gene Symbol: BCL2
BCL2
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 AlteredExpression BEFREE In early stage FL, both circulating levels of BCL2/IGH+ cells at diagnosis and MRD status during follow-up bear prognostic implications. 31385309

2020

Entrez Id: 613
Gene Symbol: BCR
BCR
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE Rearrangements of T- and B-cell receptor (TCR and BCR) genes are useful markers for clonality assessment as well as for minimal residual disease (MRD) monitoring during the treatment of haematological malignancies. 31587259

2020

Entrez Id: 2322
Gene Symbol: FLT3
FLT3
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE Consolidation chemotherapy maintained a relatively favorable outcome (3-year CIR, 29%; 3-year RFS, 71%) in patients with intermediate cytogenetics, negative FLT3-ITD, and MRD negativity. 30773106

2019

Entrez Id: 8163
Gene Symbol: CDR3
CDR3
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. 31571261

2019

Entrez Id: 947
Gene Symbol: CD34
CD34
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE Multivariate analysis showed that CD34+ALDH+-H/MRD-H was an independent adverse prognostic factor for relapse. 31364309

2019

Entrez Id: 613
Gene Symbol: BCR
BCR
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. 30858550

2019

Entrez Id: 862
Gene Symbol: RUNX1T1
RUNX1T1
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 AlteredExpression BEFREE Patients with < 3-log reduction in the RUNX1-RUNX1T1 transcript level after the second consolidation therapy (defined as MRD-H) had a significantly lower 2-year RFS rate than patients with ≥ 3-log reduction (MRD-L) (P = .017). 31364309

2019

Entrez Id: 3492
Gene Symbol: IGH
IGH
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 GeneticVariation BEFREE The CD4 count was associated with PFS irrespective of IGHV mutational status, but only in patients with detectable MRD (HR, 3.51, p = 0.0004, whereas it had no prognostic impact in MRD < 10<sup>- 4</sup> patients: p = 0.6998). 31412798

2019

Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE We aimed to evaluate the genomic ETV6-RUNX1 fusion sites as a single marker for MRD quantification. 31034759

2019

Entrez Id: 2120
Gene Symbol: ETV6
ETV6
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 GeneticVariation BEFREE Clinical and biological disease characteristics did not differ between the two subgroups of adolescents, including minimal residual disease (MRD) results during initial therapy, except for ETV6-RUNX1 frequency and gender. 31629941

2019

Entrez Id: 25
Gene Symbol: ABL1
ABL1
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE BCR-ABL1 and CRLF2<sup>Re/Hi</sup><sub>,</sub> and that high CD99 mRNA levels are strongly associated with a high frequency of relapse, high proportion of positive for minimal residual disease at day 29 and poor overall survival in paediatric cohorts, which indicate that CD99 is a potential biomarker for BCP-ALL. 30484860

2019

Entrez Id: 930
Gene Symbol: CD19
CD19
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE We have presented our cohort of 14 <i>de novo</i> CD19 negative and dim B-ALLs and have highlighted the difficulties faced during diagnosis and MRD assessment of these patients. 31184238

2019

Entrez Id: 947
Gene Symbol: CD34
CD34
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE Presence of CD15 and absence of CD34 at diagnosis correlated with the high burden of MRD at the early stage of treatment. 31807115

2019

Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 AlteredExpression BEFREE Patients with < 3-log reduction in the RUNX1-RUNX1T1 transcript level after the second consolidation therapy (defined as MRD-H) had a significantly lower 2-year RFS rate than patients with ≥ 3-log reduction (MRD-L) (P = .017). 31364309

2019

Entrez Id: 2120
Gene Symbol: ETV6
ETV6
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE We aimed to evaluate the genomic ETV6-RUNX1 fusion sites as a single marker for MRD quantification. 31034759

2019

Entrez Id: 930
Gene Symbol: CD19
CD19
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE However, prior therapy with the CD19-directed, bispecific T-cell engager blinatumomab was associated with a significantly higher rate of failure to achieve MRD- remission or subsequent loss of remission with antigen escape. 31738832

2019

Entrez Id: 596
Gene Symbol: BCL2
BCL2
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 Biomarker BEFREE In 16 QC rounds between 2010 and 2017, the four laboratories received 208 bone marrow (BM) samples (126 FL; 82 MCL); 187 were analyzed, according to the EuroMRD Consortium guidelines, by both nested (NEST) polymerase chain reaction (PCR) and real-time quantitative (RQ) PCR for BCL2/IGH MBR or IGHV rearrangements. 31325190

2019

Entrez Id: 25
Gene Symbol: ABL1
ABL1
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual
0.100 AlteredExpression BEFREE This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. 30858550

2019